AXSM - Axsome Therapeutics, Inc.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 71.71

Open

$ 70.26

Bid

$ 0.00 x 0

Ask

$ 71.79 x 200

Day's Range

$ 70.21 - $ 72.43

52 Week Range

$ 55.02 - $ 98.40

Volume

272,333

Average Volume

Market Cap

3.26B

Beta (5Y Monthly)

$ 0.78

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-23-2024	12-31-2023	10-K
2	11-06-2023	09-30-2023	10-Q
3	08-07-2023	06-30-2023	10-Q
4	05-09-2023	03-31-2023	10-Q
5	02-28-2023	12-31-2022	10-K
6	11-07-2022	09-30-2022	10-Q
7	08-09-2022	06-30-2022	10-Q
8	05-02-2022	03-31-2022	10-Q
9	03-01-2022	12-31-2021	10-K
10	11-08-2021	09-30-2021	10-Q
11	08-09-2021	06-30-2021	10-Q
12	05-10-2021	03-31-2021	10-Q
13	03-01-2021	12-31-2020	10-K
14	11-05-2020	09-30-2020	10-Q
15	08-10-2020	06-30-2020	10-Q
16	05-11-2020	03-31-2020	10-Q
17	03-12-2020	12-31-2019	10-K
18	11-07-2019	09-30-2019	10-Q
19	08-08-2019	06-30-2019	10-Q
20	05-09-2019	03-31-2019	10-Q
21	03-15-2019	12-31-2018	10-K
22	11-09-2018	09-30-2018	10-Q
23	08-08-2018	06-30-2018	10-Q
24	05-08-2018	03-31-2018	10-Q
25	03-07-2018	12-31-2017	10-K
26	11-08-2017	09-30-2017	10-Q
27	08-09-2017	06-30-2017	10-Q
28	05-09-2017	03-31-2017	10-Q
29	03-07-2017	12-31-2016	10-K
30	11-14-2016	09-30-2016	10-Q
31	08-09-2016	06-30-2016	10-Q
32	05-11-2016	03-31-2016	10-Q
33	03-24-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Analyst Ratings For Axsome Therapeutics
04/10/2024 16:00:19

Cantor Fitzgerald Reiterates Overweight on...
04/10/2024 13:35:22

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $107 p...

HC Wainwright & Co. Maintains Buy on Axsom...
04/02/2024 12:53:14

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $190...

Axsome Therapeutics Has Initiated ENGAGE P...
04/01/2024 11:28:02

Mizuho Maintains Buy on Axsome Therapeutic...
03/28/2024 14:06:59

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $10...

Truist Securities Maintains Buy on Axsome ...
03/26/2024 13:23:19

Truist Securities analyst Joon Lee maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $150 price target.

tesla-to-120-here-are-10-top-analyst-forecasts-for-tuesday

Tesla To $120? Here Are 10 Top Analyst For...
03/26/2024 12:30:05

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

RBC Capital Maintains Outperform on Axsome...
03/26/2024 12:09:24

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price targe...

Citigroup Maintains Buy on Axsome Therapeu...
03/26/2024 11:34:40

Citigroup analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $125 t...

HC Wainwright & Co. Maintains Buy on Axsom...
03/26/2024 10:15:15

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the pri...

whats-going-on-neurology-focused-axsome-therapeutics-stock-on-monday

What's Going On Neurology-Focused Axsome T...
03/25/2024 16:03:43

Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant ...

Axsome Therapeutics shares are trading hig...
03/25/2024 10:41:32

Axsome Therapeutics' AXS-12 (Reboxetine) A...
03/25/2024 10:32:12

AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy se...

HC Wainwright & Co. Reiterates Buy on Axso...
03/20/2024 10:46:17

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $18...

What Analysts Are Saying About Axsome Ther...
03/19/2024 13:01:01

Axsome Therapeutics Announced The First Pa...
03/19/2024 11:01:55

Baird Initiates Coverage On Axsome Therape...
03/19/2024 08:48:40

Baird analyst Joel Beatty initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Outperform rating and announces Pri...

HC Wainwright & Co. Reiterates Buy on Axso...
03/04/2024 12:49:00

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $18...

What Analysts Are Saying About Axsome Ther...
02/27/2024 16:00:30

Mizuho Maintains Buy on Axsome Therapeutic...
02/27/2024 15:41:49

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $11...

Stock Wars: Axsome Therapeutics Vs. Global...
02/02/2022 17:27:07